TL;DR: Granza Bio is a Y Combinator Winter 2024 startup Reprogramming Immunity for Target-Specific Medicines, currently active with a team of 7.
Reprogramming Immunity for Target-Specific Medicines
Last verified:
Granza Bio is developing programmable therapeutics for the immune system. Our platform is built on the foundational discovery of immune “superkiller” attack particles — the natural ammunition used by cytotoxic immune cells to deliver potent, localized killing. By re-arming exhausted immune cells with newly programmed ammunition, Granza restores and enhances immune function. This approach enables a new class of treatments with the potential to transform diseases ranging from cancer to autoimmunity.
Built by LemStudio
Yes. Granza Bio was funded by Y Combinator in the Winter 2024 batch. Reprogramming Immunity for Target-Specific Medicines
Granza Bio is developing programmable therapeutics for the immune system. Our platform is built on the foundational discovery of immune “superkiller” attack particles — the natural ammunition used by cytotoxic immune cells to deliver potent, localized killing. By re-arming exhausted immune cells with newly programmed…
Granza Bio was part of Y Combinator's Winter 2024 batch.
Granza Bio has a team of 7 people according to Y Combinator's directory.
Granza Bio is currently listed as Active with a team of 7 in Y Combinator's directory.
Loading interactive view…